The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: A systematic review

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Harris, Rebecca C ^a   Grandjean, Louis ^b   Martin, Laura J ^c   Miller, Alexander J P ^a   Nkang, Joseph Egre N ^a   Allen, Victoria ^d   Khan, Mishal S ^a,e   Fielding, Katherine ^a,f   Moore, David A J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Extensively drug resistant; Multi drug resistant; Systematic review; Treatment delay; Tuberculosis

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; EARLY INTERVENTION; HUMAN; INTERMETHOD COMPARISON; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; SYSTEMATIC REVIEW; THERAPY DELAY; TREATMENT DURATION; TREATMENT PLANNING; WORLD HEALTH ORGANIZATION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; META ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84977640345     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1524-0     Document Type: Article

References (71)

1. Global Tuberculosis Report 2015. Geneva: World Health Organisation; 2015.
2. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organisation; 2011.
3. Van Deun A et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684-92.
4. Moher D et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-9. w64.
5. Richardson WS et al. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123(3):A12-3.
6. Haynes RBSDL, Guyatt GH, Tugwell PS. Clinical epidemiology: how to do clinical practice research. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
7. Laserson KF, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640-5.
8. Yu MC, et al. Characteristics and treatment outcomes of MDR tuberculosis in Taiwan. Int J Infect Dis. 2014;21(Supplement 1):57.
9. Mukherjee JS, et al. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from lima, Peru. Int J Tuberc Lung Dis. 2003;7(7):637-44.
10. Javia A, et al. Clinical profile of MDR-TB patients and their early response to DOTS PLUS: An Indian perspective. Eur Respir J. 2013;42(Suppl 57).
11. Loveday M, et al. Community-based care vs. Centralised hospitalisation for MDRTB patients, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2015;9(2):163-71.
12. Ganzaya S, et al. Countrywide audit of multidrug-resistant tuberculosis and treatment outcomes in Mongolia. Public Health Action. 2013;3(4):333-6.
13. Van Der Walt M, et al. Culture conversion rates of multidrug resistant (MDRTB) patients treated in the community versus an inpatient setting in a rural area of the Western Cape (WC) of South Africa. Eur Respir J. 2012;40(Suppl 56).
14. Garcia-Garcia Ma DL, et al. Drug resistance of Mycobacterium tuberculosis in Orizaba, Veracruz. Implications for the tuberculosis prevention and control program. Rev Investig Clin. 2001;53(4):315-23.
15. Dave P, et al. Has introduction of rapid drug susceptibility testing at diagnosis impacted treatment outcomes among previously treated tuberculosis patients in Gujarat, India? PLoS One. 2015;10(4):e0121996.
16. Ahmad N, et al. Management and treatment outcomes of MDR-TB: Results froma setting with high rates of drug resistance. Int J Tuberc Lung Dis. 2015;19(9):1109-14.
17. Mukherjee JS, et al. New challenges in the clinical management of drug-resistant tuberculosis. Infect Dis Clin Pract. 2002;11(6):329-339.
18. Satti H, et al. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLoS One. 2012;7(10):e46943.
19. Handayani D, et al. Profile and treatment outcome of extensive drug resistant tuberculosis (XDR-TB) patients in Persahabatan Hospital, Jakarta Indonesia. Respirology. 2013;18: 3-4. doi: 10.1111/resp.12183_2.
20. Drobniewski FA, Balabanova YM. The diagnosis and management of multiple-drug-resistant tuberculosis at the beginning of the new millenium. Int J Infect Dis. 2002;6(1):S21-31.
21. Migliori GB, et al. The XDR-TB emergency: Answers from the scientific community. Rassegna di Patologia dell'Apparato Respiratorio. 2009;24(5):319-24.
22. Otero L, et al. Time to initiation of multidrug-resistant tuberculosis treatment and its relation with outcome in a high incidence district in Lima, Peru. Trop Med Int Health. 2015;20(3):322-5.
23. Milanov V, et al. Treatment outcome and factors associated with unfavourable treatment results in cases with multidrug-resistant tuberculosis in Bulgaria for the period 2009-2010. Eur Respir J. 2012;4(2):131-7.
24. Doh HK, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;178(10):1075-82.
25. Park J, et al. Treatment outcomes and prognostic factors in Korean patients with multidrug resistant tuberculosis. Respirology. 2009;14:A170-A295. doi: 10.1111/j.1440-1843.2009.01658.x.
26. Isaakidis P, et al. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015;19(8):969-78.
27. Marks SM, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis. 2014;20(5):812-21.
28. Leimane V, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365(9456):318-26.
29. Mitnick C, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima. Peru N Engl J Med. 2003;348(2):119-28.
30. Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child. 2003;88(12):1106-11.
31. Dheda K, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375(9728):1798-807.
32. Kim H-R, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45(10):1290-5.
33. Geerligs WA, et al. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis. 2000;4(8):758-64.
34. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis. 1998;2(11):877-84.
35. Flament-Saillour M, et al. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med. 1999;160(2):587-93.
36. Keshavjee S, et al. Treating multidrug-resistant tuberculosis in Tomsk, Russia. Ann N Y Acad Sci. 2008;1136(1):1-11.
37. Chan ED, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004;169(10):1103-9.
38. Goble M, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328(8):527-32.
39. Keshavjee S, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372(9647):1403-9.
40. Wood AJJ, Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329(11):784-91.
41. Leimane V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J. 2010;36(3):584-93.
42. Ettehad D, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(6):449-56.
43. Orenstein EW, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153-61.
44. Kwon YS, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008;47(4):496-502.
45. Heller T, et al. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2010;14(4):420-6.
46. Loveday M, et al. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2012;16(2):209-15.
47. Shin SS, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010;182(3):426-32.
48. Mpagama SG, et al. Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania. PLoS One. 2013;8(5):e62034.
49. Zhang X et al. Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study. Tropical Med Int Health. 2015;20(11):1431-7.
50. Chan P-C, et al. Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients--a retrospective cohort study. PLoS One. 2013;8(2):e57719.
51. Li R, et al. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Lancet Global Health. 2015;3(4):e217-28.
52. Seddon JA, et al. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax. 2014;69(5):458-64.
53. Gandhi NR, et al. HIV coinfection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181(1):80-6.
54. Velásquez GE, et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014;59(1):9-15.
55. Gegia M, et al. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011. Int J Tuberc Lung Dis. 2013;17(5):624-9.
56. Schnippel K, et al. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register. Int J Infect Dis. 2015;39:89-94.
57. Mohr E, et al. Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa. Trans R Soc Trop Med Hyg. 2015;109(7):425-32.
58. Mirsaeidi SM, et al. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. Int J Infect Dis. 2005;9(6):317-22.
59. Jeon DS, et al. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector. J Korean Med Sci. 2011;26(1):33-41.
60. Charles M, et al. Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti. AmJTrop Med Hyg. 2014;91(4):715-21.
61. Helbling P, et al. Treatment outcomes of multidrug-resistant tuberculosis in Switzerland. Swiss Med Wkly. 2014;144:w14053.
62. Drobac PC, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006;117(6):2022-9.
63. Cox H, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis. 2014;18(4):441-8.
64. Seddon JA, et al. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis. 2012;54(2):157-66.
65. Piubello A, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18(10):1188-94.
66. Bonilla CA, et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One. 2008;3(8):e2957.
67. Singla R, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis. 2009;13(8):976-81.
68. Kipiani M, et al. Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59(11):1559-66.
69. Holtz TH, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144(9):650-9.
70. Park JK, et al. Treatment outcomes and prognostic factors in patients with multidrug-resistant tuberculosis in Korean private hospitals. Tuberc Respir Dis. 2010;69(2):95-102.
71. Kranzer K, et al. The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis. 2013;17(4):432-46.